NMRA Neumora Therapeutics Inc.

52-Wk High	$0.00
52-Wk Low	$0.00

Fundamentals

Neumora Therapeutics (NASDAQ:NMRA) Trading 4.6% HigherZolmax • 18 days ago

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA Get Free Report) traded up 4.6% on Friday . The stock traded as high as $11.21 and last traded at $11.09. 32,521 shares were traded during...

Share to Feed

Insider Buying: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Major Shareholder Purchases 30,192 Shares of StockTicker Report • 20 days ago

Neumora Therapeutics, Inc. (NASDAQ:NMRA Get Free Report) major shareholder Arch Venture Partners Xii, Llc purchased 30,192 shares of the businesss stock in a transaction that occurred...

Analyst Expectations for Neumora Therapeutics's FutureBenzinga • 22 days ago

Neumora Therapeutics reports Q3 EPS ($1.14) vs. ($1.06) last yearThe Fly • 29 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobe Newswire • 29 days ago

Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24 Progressing NMRA-511 and NMRA-266 toward near-term clinical...

Neumora Therapeutics to Participate in Upcoming Conferences in NovemberGlobe Newswire • about 1 month ago

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...

Neumora Therapeutics, Inc.'s (NASDAQ:NMRA) Quiet Period Will End TomorrowTicker Report • about 1 month ago

Neumora Therapeutics (NASDAQ:NMRA Get Free Report) quiet period is set to end on Wednesday, October 25th. Neumora Therapeutics had issued 14,710,000 shares in its IPO on September...

Neumora Therapeutics (NASDAQ:NMRA) Receives New Coverage from Analysts at Bank of AmericaTicker Report • about 2 months ago

Bank of America initiated coverage on shares of Neumora Therapeutics (NASDAQ:NMRA Free Report) in a research note released on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy...

Neumora Therapeutics appoints Lenz as EVP, Head of Research, DevelopmentThe Fly • about 2 months ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and DevelopmentGlobe Newswire • about 2 months ago

Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicinesWATERTOWN, Mass., Oct...